Abstract
Introduction Benralizumab (BR) has demonstrated efficacy in the treatment of severe uncontrolled eosinophilic asthma. Our aim is to describe and analyse response factors to BR in a cohort of patients with severe uncontrolled asthma after at least 12 months of treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
